Siemens Healthineers Shape 23 Keynote
Hear from healthcare leaders like Dr. Jerome Adams, the 20th Surgeon General of the United States & Director of Health Equity at Purdue University, about how to address the challenges posed by cancer, how high-quality care can be brought to more patients, and how to address the workforce crisis.
Highlight Product and Topics
Related episodes
From automation to impact: How AI gives time back
From innovation to impact: How AI elevates patient care
Scaling healthcare access: The future of cancer care
Empowering today’s workforce for tomorrow
Pioneering breakthroughs to provide healthcare access for all
How to turn workforce challenges into opportunities
Siemens Healthineers Shape 22 Keynote
Siemens Healthineers Shape 21 Keynote
*The products are still under development and not commercially available yet. Its future availability cannot be ensured. Siemens Healthineers neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
In the U.S. the ELF Test is not for use in the diagnosis of NASH or for the staging of fibrosis. The ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events.